Skip to content
Bored Studies
Recruiting

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

AtaCor Medical, Inc. · NCT07324031

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
280
US sites recruiting
12
Study start
July 2, 2026
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.

The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.

Being studied: Atala™ lead and EV-ICD Pulse Generator

Conditions: Ventricular Arrythmia; Ventricular Fibrillation; Ventricular Tachycardia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • At least 18 years old
  • Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion Criteria

  • Patients who cannot read or write
  • Expected survival \< 1 year
  • Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  • Participation in any concurrent clinical study without prior approval from the Sponsor
  • Inability or unwillingness to provide informed consent to participate in the study
  • Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
  • Circumstances that may prevent data collection or completion of specified follow-up visits
  • Allergies to any device materials listed in the Instructions for Use (IFU)
  • Contraindication for temporary suspension of oral/systemic anticoagulation
  • Known history of lung disease with FEV1 \< 1.0 Liter

Device Related

  • Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
  • Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  • Any known need for MRI prior to approval of MRI conditional labeling

Anatomy Related

  • Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
  • Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
  • Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
  • Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
  • History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
  • Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  • Surgically corrected congenital heart disease (not including catheter-based procedures)

Cardiac Related

  • Indication for permanent bradycardia pacing or cardiac resynchronization therapy
  • Decompensated heart failure
  • Currently on inotropic therapy
  • Known history of pericardial disease, pericarditis or mediastinitis
  • Risk factors associated with defibrillation testing:
  • Severe aortic stenosis
  • Current Intracardiac LA or LV thrombus
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Hemodynamic instability
  • Unstable angina
  • Recent stroke or transient ischemic attack (within the last 3 months)
  • Known inadequate external defibrillation
  • LVEF \< 20% (most recent assessment; must be within 180 days of consent)
  • LVEDD >70 mm (most recent assessment; must be within 180 days of consent)

Recruiting US locations

  • St. Bernards Heart and Vascular

    Jonesboro, AR 72401

    Site contact: Devi Nair, MD

  • Mount Sinai Medical Center of Florida

    Miami Beach, FL 33140

    Site contact: Raul Weiss, MD

  • Emory University

    Atlanta, GA 30308

    Site contact: Mikhael El Chami, MD

  • Endeavor Health

    Glenview, IL 60026

    Site contact: Mark Metzl, MD

  • Baptist Health

    Lexington, KY 40503

    Site contact: Johan Aasbo, DO

  • John Hopkins Medical

    Baltimore, MD 21287

    Site contact: Edward Powers, MD

  • Mayo Clinic

    Rochester, MN 55902

    Site contact: Paul Friedman, MD

  • Northwell Health

    Manhasset, NY 11030

    Site contact: Laurence Epstein, MD

  • Advocate/Atrium Health - Sanger Heart and Vascular

    Charlotte, NC 28204

    Site contact: Satish Misra, MD

  • Advocate/Atrium Health - Wake Forest Baptist

    Winston-Salem, NC 27157

    Site contact: Satish Misra, MD

  • The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, OH 45219

    Site contact: Daniel Pelchovitz, MD

  • Texas Cardiac Arrhythmia Research

    Austin, TX 78705

    Site contact: Amin Al-Ahmad, MD

Study contacts (from the official record)

  • Sarah Hase, BS, CCRA · +1 949-545-9820 · sarah@atacor.com
Parasternal Extravascular ICD System Pivotal Clinical… (NCT07324031) | Bored Studies